PF-06882961

Eli Lilly's oral GLP-1 receptor agonist orforglipron demonstrated significant efficacy in Phase 3 clinical trials, potentially expanding the company's dominance in the rapidly growing GLP-1 market.

Biolexis Therapeutics has successfully resolved the cryoEM structure of BLX-7006, confirming a first-in-class allosteric activation mechanism for the GLP-1 receptor that differs from all existing approaches.

Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action.

Kailera Therapeutics' HRS9531, a dual GLP-1/GIP receptor agonist, demonstrated a 21.1% placebo-adjusted weight reduction in Phase II trials over 36 weeks.

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.